Avelumab did not improve progression-free survival when given concurrently with chemotherapy or as maintenance.
Most adverse events in the olaparib arm were manageable with supportive treatment or dose modifications.
PARP inhibitor use increased regardless of BRCA mutation status.
Researchers analyzed recent trends in cervical cancer incidence and mortality and made predictions for the next 15 years.
More research is needed before radiomics can be used in clinical practice, according to researchers.
Factors other than access may affect differences in survival, according to researchers.
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.
Individualized niraparib dosing should be considered standard practice, according to researchers.
Among patients with a higher risk of metastasis, sentinel lymph node mapping had a sensitivity of 96.3%.
The disparity is due to the greater prevalence of fibroids and nonendometrioid histologic type in Black women, according to researchers.
Genetic variations in the PAX8, CLPTM1L, and HLA genes were found to be associated with a high risk of developing cervical cancer.
The results raise concern about potential local tumor spill, according to researchers.
There was no improvement in progression-free or overall survival.
Findings seen in BRCA1 and BRCA2 mutation carriers; reduction greater with longer duration of use in BRCA1 carriers.
Rucaparib prolonged progression-free survival.
There was an improvement in second progression-free survival, but not overall survival, with niraparib.
There was no benefit with atezolizumab, regardless of PD-L1 status.
Researchers observed a high rate of long-term local control with MRI-guided adaptive brachytherapy after chemoradiotherapy.
Progression-free and overall survival were inferior with single-agent carboplatin.
A minority of women met criteria to exit cervical cancer screening.